Ignite Creation Date:
2024-05-06 @ 3:57 AM
Last Modification Date:
2024-10-26 @ 11:41 AM
Study NCT ID:
NCT02413827
Status:
TERMINATED
Last Update Posted:
2017-04-07
First Post:
2015-03-25
Brief Title:
A Study of Varlilumab Anti-CD27 and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Sponsor:
Celldex Therapeutics
Organization:
Celldex Therapeutics
Organization Data
Organization:
Celldex Therapeutics
Class:
INDUSTRY
Study ID:
CDX1127-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Celldex Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None